	A 1: 4: AI	
Notice of Allowability	Application No.	Applicant(s)
	10/802,955	MICHAL ET AL.
	Examiner	Art Unit
	Allison M. Ford	1651
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>telephonic interview of 9/13/06</u> .		
2. The allowed claim(s) is/are <u>1,3,5-8,19-22 and 63-72</u> .		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 1. ☐ Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)	_	
1. Notice of References Cited (PTO-892)	5. Notice of Informal Pa	, ,
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary Paper No./Mail Dat	(PTO-413), e
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. 🛛 Examiner's Amendm	nent/Comment
4. Examiner's Comment Regarding Requirement for Deposit	8. Examiner's Stateme	nt of Reasons for Allowance
of Biological Material	9.	

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Shelly Cobos on 13 September 2006.

The application has been amended as follows:

Please re-write claim 3 as follows:

-- The method of claim 1, wherein the donor cells are diploid and both chromosomal copies of a gene for α -1,3-galactosyltransferase have been disrupted.--

Please re-write claim 8 as follows:

-- Claim 8. The method of claim 1, wherein the donor cells comprise an expression vector encoding a detectable polypeptide that is operably linked to a promoter.--

Please re-write claim 19 as follows:

-- Claim 19. A method, comprising:

identifying an infarct region within a ventricle of a subject;

applying a pacing therapy to the ventricle to pre-excite the infarct region to contract during systole at a time before contraction of the ventricle initiated by the His Purkinje conduction network; and percutaneously delivering at least one non-immunogenic cell to the infarct region after applying the pacing therapy. --

Please re-write claim 20 as follows:

Art Unit: 1651

-- Claim 20. The method of claim 19, wherein the at least one non-immunogenic cell comprises donor cells from a non-antigenic line of swine cells that do not express α-1,3-galactosyltransferase (GGTA1). --

Please re-write claim 68 as follows:

-- Claim 68. The method of claim 19, wherein the at least one non-immunogenic cell has a property that stimulates a healing response in the ventricle. --

Please re-write claim 69 as follows:

-- Claim 69. The method of claim 22, wherein the modifying comprises one of increasing or reducing the pacing. --

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Allison M. Ford whose telephone number is 571-272-2936. The examiner can normally be reached on 7:30-5 M-Th, alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/802,955 Page 4

Art Unit: 1651

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Leon B Lankford Jr Primary Examiner